(SXTP) 60 Degrees Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SXTP) 60 Degrees Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This 60 Degrees Pharmaceuticals, Inc. BCG Matrix is a company-specific analysis used to see which products or business units may be Stars, Cash Cows, Question Marks, or Dogs. The page already shows a real preview of the report content, so you can review the actual format and insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
0 confirmed Star assets
60 Degrees Pharmaceuticals has one approved product, ARAKODA (tafenoquine), and several investigational programs, but none is publicly shown as a high-share leader in a fast-growing market at end-2025. So the company has 0 confirmed Star assets in strict BCG terms. Without a clear product that combines rapid market growth with dominant share, no asset fits the Star bucket.
1 commercial product only
60 Degrees Pharmaceuticals, Inc. has only one commercial product, ARAKODA, so its public portfolio is still narrow. A single marketed drug is not a Star unless it also shows strong growth and clear market leadership, and the disclosed data do not prove that mix. The company’s 2025 filings still point to a small revenue base and limited scale, so this looks more like a niche product than a Star.
2010-founded, development-heavy profile
Founded in 2010, 60 Degrees Pharmaceuticals, Inc. still centers on infectious-disease R&D, with value tied more to pipeline progress than to mature product scale. As of FY2025, that profile still looks pipeline-led rather than Star-like, because growth depends on clinical and regulatory wins, not steady large revenue.
No disclosed blockbuster revenue
In 2025 and 2026 public filings, 60 Degrees Pharmaceuticals, Inc. did not disclose blockbuster-scale revenue, so there is no evidence of a Star-level cash and share profile. Without that scale, the product base stays narrow and the Star label is not supported.
- No blockbuster revenue disclosed
- Star test not met
- Commercial base remains limited
No dominant market-share leader disclosed
60 Degrees Pharmaceuticals, Inc. does not show a clear BCG Star. Stars need high growth plus share leadership, but the portfolio description does not identify any product that leads its category, and the closest assets are still in clinical development.
That means the company’s pipeline may have upside, but it is not yet a market-share leader.
- No disclosed category leader
- Assets remain in clinical stages
- Star criteria not yet met
60 Degrees Pharmaceuticals Has No BCG Star in FY2025/FY2026
60 Degrees Pharmaceuticals, Inc. has no disclosed Star in FY2025/FY2026. ARAKODA is the only marketed product, but public filings do not show category-leading share or blockbuster-scale revenue, so it does not meet the BCG Star test.
| Item | FY2025/FY2026 view |
|---|---|
| Star assets | 0 |
| Marketed products | 1 (ARAKODA) |
| Revenue scale | No blockbuster disclosure |
| BCG Star status | Not met |
What is included in the product
Detailed Word Document
BCG Matrix snapshot for 60 Degrees Pharmaceuticals: identifies Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
Quick BCG matrix view of 60 Degrees Pharmaceuticals to pinpoint products, prioritize capital, and cut portfolio guesswork.
Reference Sources
Provides a traceable source trail for 60 Degrees Pharmaceuticals, Inc. that boosts credibility and supports faster, better decisions.
Cash Cows
Arakoda FDA approved
Arakoda, FDA-approved in 2018, is 60 Degrees Pharmaceuticals, Inc.'s malaria prophylaxis product and the clearest Cash Cow in its portfolio. Approved medicines can support repeat prescriptions and steadier revenue than R&D-stage assets, which matters for a small specialty pharma company. It is the company's best shot at durable cash flow while it scales.
Malaria prophylaxis revenue base
Malaria prophylaxis is 60 Degrees Pharmaceuticals, Inc.'s only marketed use, so this sits in a narrow, mature niche on the low-growth side of the BCG matrix. If sales stay stable, the revenue base can help fund pipeline work and overhead. In 2025, the product mix was still concentrated in malaria prevention, which supports cash generation but limits big growth.
Tafenoquine commercial brand
Arakoda, which uses tafenoquine as its active drug, is 60 Degrees Pharmaceuticals, Inc.'s only commercialized asset and the clearest Cash Cow in its BCG mix. Unlike the company’s research programs, it already has market traction, so it can generate cash while pipeline assets still face trial risk. That shift from "question mark" to sold product is the key value driver here.
U.S. specialty-pharma channel
60 Degrees Pharmaceuticals, Inc. treats its U.S. specialty-pharma channel as the clearest Cash Cow because the approved product, ARAKODA, is sold through specialty prescribing in the United States, where a narrow prescriber base can still support strong unit economics. In 2025, the U.S. market remained the main revenue engine, so modest volume can still be more cash-generative than the rest of the lineup.
The channel fits the BCG Cash Cow profile: mature product, focused demand, and higher pricing power than mass-market drugs. One line matters most: low volume does not mean low value when prescribing is specialized.
- U.S.-focused sales drive the mix
- Specialty prescribing supports margins
- Approved product carries the cash flow
Pipeline funding source
60 Degrees Pharmaceuticals, Inc.'s approved product is the only clear internal cash source in the portfolio, so it fits BCG Cash Cow logic: one marketed asset funds the next wave of R&D. That matters because the rest of the business depends on this operating cash, not on a broad, self-funding product base.
- Approved product = main cash engine
- Funds research and development
- Pipeline depends on it
ARAKODA Remains 60 Degrees’ Cash Cow in 2025
ARAKODA is 60 Degrees Pharmaceuticals, Inc.'s only marketed asset, so it is the clear Cash Cow in the BCG Matrix. In 2025, U.S. specialty prescribing and a narrow malaria-prevention niche kept it as the main cash source, while pipeline assets stayed R&D-heavy.
| Item | 2025 |
|---|---|
| Cash Cow | ARAKODA |
| Role | Main cash engine |
What You See Is What You Get
60 Degrees Pharmaceuticals, Inc. Reference Sources
This preview shows the exact 60 Degrees Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. No sample pages, no watermarks, and no hidden content—just the full, ready-to-use file. Once purchased, the same professionally formatted report is available for immediate download and use.
Dogs
0 clear Dogs disclosed
60 Degrees Pharmaceuticals, Inc. discloses no clear Dogs in its portfolio. The mix is mainly approved assets and clinical-stage programs, so there is no mature product with both low growth and low market share to flag.
Based on the available facts, the closest fit still does not qualify as a Dog because the company has no obvious legacy cash drain. The BCG read is simple: no disclosed Dog, only pipeline and approved-product exposure.
No legacy brand underperforms publicly
60 Degrees Pharmaceuticals, Inc. does not show a large legacy brand that is losing relevance, so it does not fit the classic Dogs profile. Dogs are usually old, weak-share products in slow markets, but no such publicly described asset stands out here. In FY2025, the company’s smaller revenue base and limited product mix still point more to early-stage concentration than to a fading franchise.
No divestiture candidate named
60 Degrees Pharmaceuticals, Inc. does not name any unit for sale or shutdown, so a dog call is not supportable. The disclosed portfolio is very small, with just one marketed product, so there is no clear low-return division to isolate. Without segment-level revenue or margin data for 2025/2026, tagging a divestiture candidate would be speculative.
Development assets are not Dogs yet
Clinical-stage programs are not Dogs just because they are risky. They turn into Dogs only if they keep low share in a low-growth market or fail to win adoption. 60 Degrees Pharmaceuticals, Inc. disclosures do not confirm that outcome.
The latest filings still point to development-stage value, not a dead end. One line: risk is not the same as Dog status.
Low share alone is not enough
Need weak growth plus poor uptake
Current disclosures do not prove that
Dog risk is future, not current
Dog risk here is still future-state, not current: 60 Degrees Pharmaceuticals, Inc. has not publicly shown a late-stage program that has already stalled into a clear Dog bucket as of end-2025. In small biotech, that can change fast if a Phase 3 spend cycle ends without approval, partner support, or a clear path to cash flow.
That matters because one failed late-stage readout can turn sunk R&D into weak asset value and force dilution or cuts. For this company, the Dog label is a watch item, not a confirmed 2025 category.
- Late-stage failure can create Dog risk
- Small biotechs face faster value decay
- End-2025 status: not confirmed Dog
No Confirmed Dogs: 60 Degrees Pharmaceuticals Stays on Watch
60 Degrees Pharmaceuticals, Inc. shows no confirmed Dogs in FY2025/FY2026 disclosures. The portfolio looks concentrated in one marketed product plus clinical-stage programs, so there is no clear low-share, low-growth asset to flag. In one line: no disclosed Dog, only watch-list risk.
| Item | FY2025/FY2026 read |
|---|---|
| Dogs | None disclosed |
| Portfolio mix | One marketed product, clinical-stage programs |
| Dog risk | Watch item, not confirmed |
Question Marks
Tafenoquine Phase IIb COVID-19
Tafenoquine Phase IIb COVID-19 is still a development-stage program, so it has no disclosed market share yet. In a high-interest infectious-disease market where 2025 COVID-19 drug sales still matter, the asset is betting on trial data, not current revenue. That makes it a classic Question Mark for 60 Degrees Pharmaceuticals, Inc.
Tafenoquine Phase IIA babesiosis
Tafenoquine for babesiosis is still investigational, even with 60 Degrees Pharmaceuticals, Inc.'s patent license agreement with Tufts Medical Center. The Phase IIA program has to show clear clinical benefit and real demand before it can matter financially. That mix of high upside and low current market share fits Question Mark territory.
Tafenoquine Phase IIA fungal pneumonias
Tafenoquine Phase IIA fungal pneumonias sits in the Question Marks bucket: it is still early-stage, with no disclosed sales, market share, or commercial footprint. It is a cash-consuming R&D bet, and 60 Degrees Pharmaceuticals must fund more clinical work before any adoption case can form.
Tafenoquine Phase IIA candidiasis
Tafenoquine Phase IIA candidiasis is a non-commercial 60 Degrees Pharmaceuticals, Inc. program. It fits Question Mark: the antifungal market can be meaningful if the data hold up, but the asset is still early and not a leader. Phase IIA means proof is still limited, so uptake and value remain binary.
- Early-stage, no commercial traction
- Upside depends on strong clinical data
- High risk, uncertain share capture
Celgosivir for Zika dengue respiratory viruses
Celgosivir is being developed by 60 Degrees Pharmaceuticals, Inc. for Zika, dengue, and respiratory viruses, but all uses remain investigational. As of end-2025, no market share was disclosed, and the addressable markets are highly contested. That makes Celgosivir a classic Question Mark in the BCG Matrix: high growth hope, low proof.
- Multiple viral targets, no approved use
- End-2025 market share: not disclosed
- Competitive and high-uncertainty profile
- Question Mark, not yet a cash engine
60 Degrees Pharma’s Pre-Revenue Question Marks Still Need a Trial Win
60 Degrees Pharmaceuticals, Inc.'s Question Marks are all pre-revenue and still depend on trial wins, not market share. Tafenoquine programs for COVID-19, babesiosis, fungal pneumonias, and candidiasis remain early-stage; Celgosivir is also investigational for Zika, dengue, and respiratory viruses. Each has upside, but none has proved commercial traction yet.
| Asset | Status | BCG |
|---|---|---|
| Tafenoquine | Phase IIb/IIA | Question Mark |
| Celgosivir | Investigational | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.